A Needle Technique for Achilles Tendon Lengthening in Pediatric Patients: A Prospective Study on Efficacy, Safety, and Feasibility

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-16
SponsorVestre Viken Hospital Trust

About this trial

For years, we have used a minimally invasive and biological variant of Achilles tendon lengthening using a needle inserted into the Achilles tendon so that it is weakened and can be gradually stretched to the desired length. So far, no negative effects, complications or tendon problems have been observed. A prospective study of a cohort of children and adolescents is planned where there is an indication for Achilles lengthening, such as spastic or non-spastic contracture and toe walking that results in an unwanted shortening of the Achilles tendon that makes walking difficult. We plan to include up to 50 children and adolescents over a two-year period and follow them closely for the first year after surgery. Pediatric physiotherapists will perform all clinical examinations to limit observer bias, and a radiologist will examine the tendon tissue with ultrasound before and one year after surgery to check anatomical conditions. The study will examine safety, effectiveness and feasibility of using the method, and anatomy, patient satisfaction and quality of life.

Eligibility criteria

Qualifiers

Age: 5-16 years

Consent from parents/guardians

Equinus foot with dorsiflexion ≤ 0 degrees with the knee extended and the heel in neutral position.

Symptomatic equinus foot, meaning a foot position causing pain, discomfort, increased fatigue, etc.

Disqualifiers

Unwillingness to participate, lack of consent

Previous surgical Achilles tendon lengthening, e.g., for clubfoot

Received BoNT-a injection in the triceps surae within the last 6 months

Contracture in the ankle joint, i.e., equinus position not due to a tight Achilles tendon

Trial design

Treatments tested in this trial

  • Needle tendon lengthening technique

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators